Taken together, these results indicate that while both linear HER-GLP-1 and branched HER-GLP-2 molecules induced RAFT-specific IgGs that bind to human tumor cell lines expressing the native Tn antigen, the branched HER-GLP-2 appeared to be a stronger B-cell immunogen than the linear HER-GLP-1. This evidence concerns the gene GCG and neoplasm.